IONS
Ionis Pharmaceuticals, Inc.
September 14, 2026 · pre-market
- Rarity
- 1.19
- Peak move
- −5.32%
- Float cap
- $8.7B
Ionis Pharmaceuticals is a commercial-stage biotechnology company that discovers and develops RNA-targeted medicines for serious diseases. It markets seven therapies, including treatments for familial chylomicronemia syndrome, hereditary angioedema, hereditary transthyretin-mediated amyloidosis, spinal muscular atrophy, SOD1-ALS, and related rare disorders. Its medicines are sold to patients in the U.S., Europe, and other regions directly and through partners such as AstraZeneca, Biogen, and Sobi.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingGoldman Sachs lowered its price target on Ionis Pharmaceuticals to $56 from $69 while maintaining a Hold/neutral rating in a research note dated September 14, 2026.
analyst_ratingGuggenheim cut its price target on Ionis Pharmaceuticals to $80 from $89 while keeping a Buy rating, citing a poll of 30 U.S. cardiologists and lipidologists projecting about 40% year-end 2027 adoption of Tryngolza in severe hypertriglyceridemia versus management guidance of more than $3 billion in peak sales.
executive_remarkIonis CEO Brett Monia said at the Wells Fargo 21st Annual Healthcare Conference that the company sees no path forward for pelacarsen after the Phase 3 Lp(a)-HORIZON failure, and that AstraZeneca has made no definitive decision on whether eplontersen has a path in ATTR cardiomyopathy after the CARDIO-TTRansform primary endpoint miss.
clinical_readoutNovartis reported that the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial of pelacarsen, discovered by Ionis and licensed to Novartis in 2019, lowered Lp(a) levels about 75-80% but missed its primary endpoint, showing no reduction in the four-point MACE composite versus placebo.
clinical_readoutIonis reported Phase 3 NEURO-TTR topline results for inotersen in familial amyloid polyneuropathy, meeting efficacy endpoints on neuropathy and quality of life but with three serious thrombocytopenia adverse events, including one death from intracranial haemorrhage, and four patients discontinuing for renal issues.